Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer

Endobronchial carcinoma develops through a continuum of morphologically recognizable pre-neoplastic changes. At present, no marker has been identified that can reliably predict the biological behavior of these lesions. Endobronchial lesions ( n=39) sampled from patients ( n=20) without clinically ov...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2003-05, Vol.40 (2), p.165-172
Main Authors: Breuer, Roderick H.J., Snijders, Peter J.F., Sutedja, Thomas G., v.d. Linden, Hans, Risse, Elle K.J., Meijer, Chris J.L.M., Postmus, Pieter E., Smit, Egbert F.
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Biomarkers, Tumor - metabolism
Bronchi - pathology
Bronchial Neoplasms - metabolism
Bronchial Neoplasms - pathology
Disease Progression
Endobronchial lesions
Epithelial Cells - pathology
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Immunoenzyme Techniques
LIFE
Male
Medical sciences
Middle Aged
Pneumology
Precancerous Conditions - metabolism
Precancerous Conditions - pathology
Premalignant
Prognosis
Prospective Studies
Respiratory Mucosa - pathology
Suprabasal p53 immunostaining
Tumor Suppressor Protein p53 - metabolism
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endobronchial carcinoma develops through a continuum of morphologically recognizable pre-neoplastic changes. At present, no marker has been identified that can reliably predict the biological behavior of these lesions. Endobronchial lesions ( n=39) sampled from patients ( n=20) without clinically overt lung cancer, were analyzed by immunohistochemistry (IHC) for abnormal expression regarding the p53 protein, i.e. suprabasal p53 expression. Clear suprabasal p53 immunostaining was found in two (12%) of the hyperplastic or squamous metaplastic lesions, in one (10%) of the mildly or moderately dysplastic lesions and in nine (75%) of the severely dysplastic or carcinoma in situ (CIS) lesions. Suprabasal p53 immunostaining was found significantly more frequent in severe dysplasia or CIS ( P
ISSN:0169-5002
1872-8332
DOI:10.1016/S0169-5002(03)00029-1